Rexahn Pharmaceuticals, Inc.

Product Pipeline

A Diverse Portfolio of Novel Oncology Assets

Our mission at Rexahn Pharmaceuticals is to develop innovative, targeted cancer therapies with the potential to improve survival and quality of life in cancer patients. Building on a strong foundation in cancer research and discovery, we have assembled a diverse portfolio of novel oncology assets that includes two clinical-stage investigational anti-cancer compounds currently in Phase 2 clinical trials and additional compounds in preclinical development.

Candidate & Indication Collaborators Preclinical Phase 1 Phase 2

RX-3117

Metastatic Pancreatic Cancer

Advanced Bladder Cancer

Additional Cancer Indications

 BioSense
Preclinical complete
Preclinical complete
Preclinical in progress
Phase 1 complete
Phase 1 complete
Phase 1 not started
Phase 2 in progress
Phase 2 in progress
Phase 2 not started

RX-5902

Metastatic Triple Negative Breast Cancer
Preclinical complete
Phase 1 complete
Phase 2 in progress

RX-0301

Hepatocellular Carcinoma

 Haichang
Preclinical in progress
Phase 1 not started
Phase 2 not started

RX-3117

A Novel Small Molecule Nucleoside Analog Targeted to Cancer Cells

RX-3117 is a novel, oral small molecule nucleoside compound being developed for the treatment of metastatic pancreatic cancer and advanced bladder cancer. RX-3117 is a prodrug that is activated in tumor cells by a kinase, UCK2. The targeted activation offers the potential for better efficacy and safety relative to older nucleoside analogues.

View RX-3117

RX-5902

First-in-Class Small Molecule Modulator of the β-catenin/Wnt Pathway

RX-5902 modulates the activity of the β-catenin/Wnt pathway which is a key pathway involved in cancer cell growth and proliferation, oncogene expression and activation of the immune response to cancer. RX-5902 modulates the pathway through inhibition of phosphorylated p68 which is over-expressed in tumor cells. RX-5902 is in Phase 2 clinical trials for triple negative breast cancer (TNBC) and will also be evaluated in combination with Keytruda® (pembrolizumab) for TNBC in collaboration with Merck.

View RX-5902

Clinical Trial Studies

View Clinical Trials